Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer Center.
GRIm
LIPI
MDA-ICI
MDACC
MDA + NLR
RMH
immunotherapy
phase I
prognostic scores
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 May 2021
15 May 2021
Historique:
revised:
17
09
2020
received:
04
05
2020
accepted:
12
10
2020
medline:
25
11
2020
pubmed:
25
11
2020
entrez:
24
11
2020
Statut:
ppublish
Résumé
We compared the performance of six prognostic scores (Royal Marsden Hospital, MDACC: MD Anderson Clinical Center and MDACC + NLR: neutrophil-to-lymphocyte ratio, MD Anderson - immune checkpoint inhibitors (MDA-ICI), GRIm: Gustave Roussy Immune Score and LIPI: Lung Immune Prognostic Index) in predicting overall survival (OS) in phase I trial patients treated with immune checkpoint inhibitors (ICI). Medical records of patients with advanced solid tumors enrolled in ICI phase I trials between 2015 and 2018 at Institut Universitaire du Cancer de Toulouse-Oncopole were reviewed. The performance of prognostic scores on OS was compared using different criteria. A total of 259 patients were included. Median age was 63 years (range: 18-83). Main primary cancers were melanoma (19%), head and neck (16%), lung (13%) and bladder (10%). With a median follow-up of 15 months (95% confidence interval [CI] = [11.6;17.5]), median OS was 12.5 months (95% CI = [10.3;16.0]). All scores were associated with OS. The MDACC, LIPI and GRIm scores performed better than the others. Concordance of risk group assignment between the scoring systems was poor. According to our results, the MDACC, GRIm and LIPI scores better suited to ICI phase I settings. Adequate scoring would allow better patient selection in early ICI trials, especially during the critical period of dose escalation, and in proof-of-concept expansion cohorts.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2502-2511Informations de copyright
© 2020 UICC.
Références
Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:2518-2527.
Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol. 2016;27:214-224.
Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet Lond Engl. 2014;384:1109-1117.
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341-351.
Voskoboynik M, Arkenau H-T. Challenges of patient selection for phase I oncology trials. Drug Discov Dev Mol Med. 2015, London: Intech Open; 2015, p. 65. https://doi.org/10.5772/59712.
Chow E, Harth T, Hruby G, et al. How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol R Coll Radiol G B. 2001;13:209-218.
Glare P, Virik K, Jones M, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ. 2003;327:195-198.
Morita T, Tsunoda J, Inoue S, Chihara S. Improved accuracy of physicians' survival prediction for terminally ill cancer patients using the palliative prognostic index. Palliat Med. 2001;15:419-424.
Arkenau H-T, Olmos D, Ang JE, de Bono J, Judson I, Kaye S. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer. 2008;98:1029-1033.
Wheler J, Tsimberidou AM, Hong D, et al. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res. 2012;18:2922-2929.
Maymani H, Hess K, Groisberg R, et al. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018;120:137-141.
Sen S, Hess K, Hong DS, et al. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer. 2018;118:763-769.
Bigot F, Castanon E, Baldini C, et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy Immune Score (GRIm-score). Eur J Cancer. 2017;84:212-218.
Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4:351-357.
Varga A, Bernard-Tessier A, Auclin E, et al. 3OApplicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials. Ann Oncol. 2019;30:i2. https://doi.org/10.1093/annonc/mdz027.001.
Stavraka C, Pinato DJ, Turnbull SJ, et al. Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials: prognostic score for phase 1 cancer trials. Cancer. 2014;120:262-270.
Füssenich LM, Desar IME, Peters MEWJ, et al. A new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer Oxf Engl. 2011;47:1152-1160.
Moons KGM, Altman DG, Reitsma JB, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162:W1-W73.
Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med. 2004;23:723-748.
Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol. 2013;13:33.
Wei Y, Royston P. Reconstructing time-to-event data from published Kaplan-Meier curves. Stata J. 2017;17:786-802.
Blanche P, Dartigues J-F, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32:5381-5397.
Arkenau H-T, Barriuso J, Olmos D, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol. 2009;27:16:2692-2696. http://dx.doi.org/10.1200/jco.2008.19.5081.
Garrido-Laguna I, Janku F, Vaklavas C, et al. Validation of the Royal Marsden Hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer. 2012;118:1422-1428.
Riley RD, Moons KGM, Snell KIE, et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ. 2019;364:k4597.
Mallett S, Royston P, Waters R, Dutton S, Altman DG. Reporting performance of prognostic models in cancer: a review. BMC Med. 2010;8:21.
Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25:127-141.
Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332:1080.
Olmos D, A'Hern RP, Marsoni S, et al. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol. 2012;30:996-1004.
Kazandjian D, Gong Y, Keegan P, et al. Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer. JAMA Oncol. 2019;5:1481. http://dx.doi.org/10.1001/jamaoncol.2019.1747.
Janssen KJM, Moons KGM, Kalkman CJ, Grobbee DE, Vergouwe Y. Updating methods improved the performance of a clinical prediction model in new patients. J Clin Epidemiol. 2008;61:76-86.
Janssen KJM, Vergouwe Y, Kalkman CJ, Grobbee DE, Moons KGM. A simple method to adjust clinical prediction models to local circumstances. Can J Anaesth. 2009;56:194-201.
Steyerberg EW, Borsboom GJJM, van Houwelingen HC, Eijkemans MJC, Habbema JDF. Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med. 2004;23:2567-2586.
van Houwelingen HC. Validation, calibration, revision and combination of prognostic survival models. Stat Med. 2000;19:3401-3415.
Mushkudiani NA, Hukkelhoven CWPM, Hernández AV, et al. A systematic review finds methodological improvements necessary for prognostic models in determining traumatic brain injury outcomes. J Clin Epidemiol. 2008;61:331-343.
Borcoman E, Kanjanapan Y, Champiat S. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30:385-396.
Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25:5218-5224.
Branchoux S, Bellera C, Italiano A, Rustand D, Gaudin AF, Rondeau V. Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: a systematic literature review. Crit Rev Oncol Hematol. 2019;137:35-42.
Buyse M, Burzykowski T, Saad ED. The search for surrogate endpoints for immunotherapy trials. Ann Transl Med. 2018;6:231. https://doi.org/10.21037/atm.2018.05.16.
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015-1026.
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-1813.
Ballman KV. Biomarker: predictive or prognostic? J Clin Oncol. 2015;33:3968-3971.
Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133-150.
Markman M. Assigning a cause for a particular outcome in oncology: a serious note of caution. Cancer. 2008;113:668-670.